Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
347
-
Total 13F shares, excl. options
-
99M
-
Shares change
-
-3M
-
Total reported value, excl. options
-
$3.58B
-
Value change
-
-$108M
-
Put/Call ratio
-
1.06
-
Number of buys
-
147
-
Number of sells
-
-180
-
Price
-
$36.13
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q3 2025
425 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q3 2025.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 347 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 99M shares
of 159M outstanding shares and own 62.33% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (21.3M shares), VANGUARD GROUP INC (15.5M shares), STATE STREET CORP (8.1M shares), Clearbridge Investments, LLC (4.64M shares), Soleus Capital Management, L.P. (3.84M shares), GEODE CAPITAL MANAGEMENT, LLC (3.44M shares), Pictet Asset Management Holding SA (1.61M shares), Hood River Capital Management LLC (1.55M shares), GOLDMAN SACHS GROUP INC (1.52M shares), and NORTHERN TRUST CORP (1.5M shares).
This table shows the top 347 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.